Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Hypertension and Obesity
NCT07919405Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Countries
- 19
01
Overview
Phase 3, randomised trial of CagriSema in hypertension (HTN) and obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in in-office systolic blood pressure at 32 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CagriSema
03
Conditions
hypertension (HTN)obesity
Beyond the preview
Go deeper on NCT07919405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919405.